Program

2nd International HIV/Viral Hepatitis Co-­Infection Meeting

(An IAS affiliated event held just prior to IAS 2015)

Overall Theme

HIV/Viral Hepatitis: Antiviral therapy development access

Specific Themes:                   

  • HCV therapeutic development and access
  • HBV prevention and management
  • Optimizing HCV treatment costs and outcomes
  • Complex issues in viral hepatitis management
  • Challenges and opportunities for scaling up viral hepatitis programs

Conference Program

Conference Program
Program – Friday, 17 July, 2015

Program – Friday, 17 July, 2015

8:00am Registration & continental breakfast in Grand Ballroom Foyer

8:45 – 10:30am

HCV therapeutic development and access

Chairs: Marina Klein & Greg Dore Room: Ballrooms A & B

8.45 – 9.00am Introductions Marina Klein (Canada)
9.00 – 9.30am Global HIV/viral hepatitis co-infection: epidemic trends and disease burden Massimo Ghidinelli (WHO)
9.30 – 10.00am Implementation of modern HCV therapy into clinical practice Jordan Feld (Canada)
10.00 – 10.30am Right to care: in resource limited and high income settings Niklas Luhmann (Medecins du Monde)

10:30 – 11:00am Break in Grand Ballroom Foyer (refreshments provided)

11:00 – 12:30pm

Prevention of viral hepatitis: Which strategies will work?

Chairs – Natasha Martin & Gail Matthews

Room: Ballrooms A & B

11.00 – 11.30am Antiviral prevention: treatment, PEP, PrEP Greg Dore (Australia)
11.30 – 12.00pm PMTC for viral hepatitis Lawrence Mbuagbaw (Canada)
12.00 – 12.30pm Modelling the impact of increased testing and treatment on the HCV epidemic Homie Razavi (CDA, USA)

12:30 – 1:30pm Lunch in Grand Ballroom Foyer

1:30 – 3:00pm

Optimising HCV treatment costs and outcomes

Chairs: Jens Lundgren & Mauro Schechter

Room: Ballrooms A & B

1.30 – 2.00pm The minimum cost to cure HCV with DAAs revisited Andrew Hill (UK)
2.00 – 2.30pm Can pricing strategies make a difference: The Brazil Experience Fabio Mesquita (Brazil)
2.30 – 3.00pm Impact of HCV cure on non-hepatic comorbidities Gail Matthews (Australia)

3:00 – 3:30pm Break in Grand Ballroom Foyer (refreshments provided)

3:30 – 5:00pm

Hepatitis Prevention and Implementation (AIDS 2015 abstracts)

Chairs: Natasha Martin & Ying-Ru Lo Room: Ballrooms C & D

HCV pathogenesis and therapeutic development (AIDS 2015 abstracts)

Chairs: Marina Klein & Jürgen Rockstroh Room: Ballrooms A & B

3.30pm  P. Easterbrook – Global systematic review and meta-analysis of the seroprevalence of HBV and HCV infection in HIV-infected persons
 A. Díaz-De Santiago – Decreasing Prevalence of HCV-HIV Coinfection (2004-2013) in Madrid, Spain
N. Martin – The impact of serosorting on Hepatitis C and HIV coinfection amongst MSM: a modelling analysis
 E. Huchet – Low Incidence of Reinfection with Hepatitis C Virus after Successful Treatment in Montreal
4.30 – 5.00pm Panel Discussion
3.30pm  F. Jean – Discovery of a novel class of naturally occurring indirect-acting antiviral agents against both HIV-1 and hepatitis C virus infection
 C. Down – The risk of cardiovascular disease and death over 10 years in HIV/HCV co-infected patients with and without steatosis
 D. Wyles – High Efficacy and Low Relapse Rates Observed with 8 or 12 Weeks of LDV/SOF STR in GT1 HCV Infected Treatment-Naïve, Non-Cirrhotic Patients with Pretreatment HCV RNA < 6 Million IU/mL
 4.30 – 5.00pm Panel Discussion

5:00 – 6:00pm Welcome drinks in Grand Ballroom Foyer

Program – Saturday, 18 July, 2015

Program – Saturday, 18 July, 2015

8:00 – 9:00 am Continental breakfast in Grand Ballroom Foyer

9:00 – 10:30am

Hot topics in HBV

Chairs: Sai Subhasree Raghavan & Pierre Côte

Room: Ballrooms A & B

9.00 – 9.30am HBV cure agenda: How far along are we? Marion Peters (U.S.A.)
9.30 – 10.00am Scaling up HBV testing & treatment: Challenges and successes Monique Andersson (S. Africa)
10.00 – 10.30am Does HBV DNA suppression reduce the risk of HCC? Henry Chan (Hong Kong)

10:30 – 11:00am Break in Grand Ballroom Foyer (refreshments provided)

11:00 – 12:30pm

Complex issues in viral hepatitis management

Chairs: Curtis Cooper & Christoph Boesecke Room: Ballrooms A & B

11.00 – 11.30am How short is short enough: optimal duration for HCV treatment Sanjay Bhagani (UK)
11.30 – 12.00pm Will resistance matter in the end? Jean Michel Pawlotsky (France)
12.00 – 12.30pm Do we already have solutions for all genotypes? Peter Ghali (Canada)

12:30 – 1:30pm Ballroom Lunch

1:30 – 3:05pm

Workshop – A focus on people who inject drugs

Moderators: Tracy Swan & Alissa Greer

Room: Ballrooms A & B

Workshop – Challenges and opportunities for scaling up viral hepatitis programs in low and middle and high income countries

Moderators: Anchalee Avihingsanon & Mark Hull

Room: Ballrooms C & D

1.35 – 1.55pm The role of Drug policy in the HCV epidemic Dan Werb (Canada)
1.55 – 2.15pm Test and treat for HCV in PWID Jason Grebely (Australia)
2.15 – 2.35pm Linking HCV treatment to addiction care

Julie Bruneau (Canada)

2.35 – 3.05pm Panel Discussion Chairs and a community member
1.35 – 1.55pm Ukraine Ludmyla Maistat (Ukraine)
1.55 – 2.15pm Mongolia

Wilbert Bannenberg (Netherlands)

2.15 – 2.35pm Wellness through continuity: First Peoples in Canada, HIV and hepatitis C Alexandra King (Canada)
2.35 – 3.05pm Panel Discussion Chairs and a community member

3:05 – 3:30 pm Break in Grand Ballroom Foyer (refreshments provided)

3:30 – 6:00 pm

Public health advocacy and access to HCV therapy

Chairs: Isabelle Andrieux-Meyer and Tracy Swan Room: Ballrooms A & B

3.30 – 3.45pm Community-based organisations role in global advocacy for HCV therapy Karyn Kaplan (TAG)
3.45 – 4.00pm Implementation of HBV HCV programs in resource limited settings: MSF operational update Isabelle Andrieux-Meyer (MSF)
4.00 – 4.15pm HBV & HCV eradications strategies for 2030 Andrew Ball (WHO)
4.15 – 5.30pm Panel discussion : Pushing the viral hepatitis eradication agenda forward

Moderator: Kathryn Gretsinger (CBC)

Key questions:

1. What are the most significant access barriers to overcome?

2. What are your plans to address it?Isabelle Andrieux-Meyer (MSF)

Andrew Ball (WHO)

Wilbert Bannenberg (HERA)

Herb Harwell (Clinton Health Access)

Mark Lallemant (DNDi)

Priti Radhakrishnan (I-MAK)

Tracy Swan (TAG)5.30 – 5.45pmAudience Questions 5.45 – 6.00pmClosing RemarksJürgen Rockstroh (Germany)


Event Organisers

2nd International HIV/Viral Hepatitis Co-­infection Meeting

Friday, July 17 – Saturday, July 18, 2015

Sheraton Vancouver Wall Centre
1088 Burrard Street, Vancouver, BC
V6Z 2R9, Canada
(604) 331-1000

Venue

Sheraton Vancouver Wall Centre
1088 Burrard Street, Vancouver, BC V6Z 2R9, Canada
(604) 331-1000

Contact Info

CIHR Canadian HIV Trials Network
588 – 1081 Burrard Street
Vancouver, BC V6Z 1Y6
Toll Free: 1-800-661-4664
Email: info@coinfectionmeeting.com

Share This